Haleon has sold its Nicotinell, Habitrol and Thrive brands to Indian pharmaceutical company Dr Reddy’s Laboratories
Healthcare giant Haleon is offloading the nicotine replacement brands it sells outside the US for £500million.
Indian pharmaceutical company Dr Reddy’s Laboratories is taking on products including Nicotinell, Habitrol and Thrive, which are sold in 30 markets around the world as lozenges, patches and gum for people who want to quit smoking.
Sensodyne and Panadol maker Haleon, which has dual London and New York listing, said it has agreed the sale as part of ongoing efforts to trim down its consumer health portfolio.
Earlier this year it sold its ChapStick lip balm brand while it offloaded athlete’s foot treatment Lamisil last year.
Haleon – which was spun off from drug giant GSK in 2022 – said its nicotine replacement therapy business outside the US generated net revenues of £217million in 2023.
DIY INVESTING PLATFORMS
AJ Bell
AJ Bell
Easy investing and ready-made portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free fund dealing and investment ideas
interactive investor
interactive investor
Flat-fee investing from £4.99 per month
eToro
eToro
Share investing: 30+ million community
Trading 212
Trading 212
Free share dealing and no account fee
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.
Compare the best investing account for you
***
Read more at DailyMail.co.uk